

PROFESSIONAL INFORMATION

SCHEDULING STATUS:

S2

PROPRIETARY NAME AND DOSAGE FORM:

DEMAZIN[®] NS REPETABS[™]

COMPOSITION:

Active Ingredients:

Each DEMAZIN NS REPETAB contains 5 mg loratadine (micronised) in the tablet coating and 120 mg pseudoephedrine sulphate, equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated while the release of decongestant in the core is delayed to ensure a long-lasting effect.

Inactive ingredients: Acacia, calcium sulphate, carnauba wax, lactose, magnesium stearate, maize starch, microcrystalline cellulose, neutral soap, oleic acid, povidone, rosin, sucrose, talc, titanium dioxide, white wax and zein.

Contains sugars: Lactose monohydrate 17 %, Sucrose 19 %

CATEGORY AND CLASS:

A.5.8 Preparations for the common cold, including nasal decongestants and antihistaminics.

PHARMACOLOGICAL ACTION:

Loratadine is a long-acting, tricyclic antihistamine with selective peripheral H₁-receptor antagonist activity.

Pseudoephedrine sulphate is an orally active vasoconstrictor which produces sustained shrinkage of congested upper respiratory mucosa through a sympathomimetic action

INDICATIONS:

DEMAZIN[®] NS REPETABS[™] are indicated for the relief of nasal and ocular symptoms of upper respiratory mucosal congestion, as in allergic and vasomotor rhinitis.

PROFESSIONAL INFORMATION

CONTRAINDICATIONS:

DEMAZIN® NS REPETABS™ are contraindicated in patients who have shown sensitivity or idiosyncrasy to either of its active components, to adrenergic agents or to other drugs of similar chemical structure and in patients receiving monoamine oxidase inhibitors, or within 14 days of stopping such treatment.

Narrow angle glaucoma, urinary retention, severe hypertension or coronary artery disease and hyperthyroidism are relative contra-indications.

The safe use of DEMAZIN® NS REPETABS™ in children under 12 years of age, or in pregnant or lactating mothers has not been established. **[SEE HUMAN REPRODUCTION]**

Safety in the elderly has not been established.

WARNING AND SPECIAL PRECAUTIONS:

DEMAZIN® NS REPETABS™ contains sugar, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption should not take DEMAZIN® NS REPETABS™

Special Precautions

In patients 60 years of age or older, sympathomimetics are also more likely to cause adverse reactions such as confusion, hallucination, convulsions, central nervous system depression and death.

Consequently, caution should be exercised when administering a repeat-action formulation to elderly patients.

Sympathomimetics should be given with caution in patients with glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, prostatic hypertrophy, urinary tract obstruction, cardiovascular disease, increased intraocular pressure or diabetes mellitus and in patients older than 60 years of age.

Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; an initial dose of one DEMAZIN® NS REPETABS™ daily is recommended.

PROFESSIONAL INFORMATION

Pseudoephedrine sulphate has been abused. At high doses subjects commonly experience an elevation of mood, decreased appetite and a sense of increased physical energy, mental capacity and alertness. Anxiety, irritability and loquacity also have been experienced. With continued use, tolerance develops; the user increases the dose and ultimately toxicity occurs. Depression may follow rapid withdrawal.

Acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction, may occur with pseudoephedrine-containing products in isolated cases. If signs and symptoms such as fever, erythema, or small (generalized) pustules are observed, patients should discontinue to use the drug and consult their physician.

Effects on Ability to Drive and Use Machinery

Loratadine lacks significant sedative effects.

Patients should, however, be warned that a small number of individuals may experience sedation. It is therefore advisable to determine individual response before driving or performing complicated tasks. This effect may be compounded by the simultaneous intake of alcohol or other central nervous system depressants.

MEDICINE/LABORATORY TEST INTERACTIONS:

Antihistamines should be discontinued approximately 48 hours prior to skin testing procedures since these medicines may prevent or diminish otherwise positive reactions to dermal reactivity indicators.

The *in vitro* addition of pseudoephedrine to sera containing the cardiac isoenzyme MB of serum creatine phosphokinase progressively inhibits the activity of the enzyme. The inhibition becomes complete over 6 hours.

When sympathomimetics are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions including hypertensive crisis may occur.

Increase in plasma concentrations of loratadine have been reported after concomitant use with ketoconazole, erythromycin or cimetidine in controlled clinical trials, but without clinically significant changes

PROFESSIONAL INFORMATION

(including electrocardiographic). Other medicines known to inhibit hepatic metabolism should be co-administered with caution until definitive interaction studies can be completed.

Sympathomimetics reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids. Increased arrhythmias may occur in conjunction with digitalis. The effect of beta-adrenergic blockers may also be reduced. Antacids increase the rate of pseudoephedrine absorption, while kaolin decreases the absorption rate.

HUMA REPRODUCTION:

Safety use of DEMAZIN® NS REPETABS™ in pregnancy and lactating mothers has not been established.

DOSAGE AND DIRECTIONS FOR USE:

Adults and children over 12 years of age

One DEMAZIN® NS REPETABS™ twice daily, without chewing the tablet.

The duration of treatment should be determined by the duration of symptoms and should not exceed 14 days.

SIDE EFFECTS:

| Table 1: The following side-effects have been reported and the frequencies are unknown: | |
|--|---|
| <i>Immune system disorders</i> | Hypersensitivity reactions including bronchospasm, angioedema and anaphylaxis |
| <i>Psychiatric disorders</i> | depression, confusion, decreased libido, hyperkinesia, agitation, apathy, euphoria, , insomnia, |
| <i>Nervous system disorders</i> | Nervousness, dizziness, thirst, hypoesthesia, paraesthesia, tremor, increase in sweating, migraine, malaise, central nervous stimulation, excitability, convulsions, rigors, anxiety, paroneiria, taste abnormality |
| <i>Eye disorders</i> | eye disorders |
| <i>Ear and labyrinth disorders</i> | vertigo , earache, tinnitus, |

PROFESSIONAL INFORMATION

| | |
|--|---|
| <i>Cardiac disorders</i> | tachycardia, postural hypotension, palpitation, hypertension, supraventricular tachyarrhythmias, cardiovascular collapse |
| <i>Vascular disorders</i> | Flushing, hypertension |
| <i>Respiratory, thoracic and mediastinal disorders</i> | Pharyngitis, rhinitis, bronchospasm, coughing, dyspnoea, nasal congestion, sneezing, nasal irritation, epistaxis. |
| <i>Gastro-intestinal disorders</i> | vomiting, nausea, abdominal distress, change in bowel habits, dyspepsia, haemorrhoids, taste abnormality, tongue discolouration, tongue disorder, eructation, dehydration |
| <i>Hepato-biliary disorders</i> | transient abnormal hepatic function, abnormal hepatic function |
| <i>Skin and subcutaneous tissue disorders</i> | pruritus, rash, urticaria, acne, alopecia |
| <i>Musculoskeletal and connective tissue disorders</i> | arthralgia, back pain , leg cramps, asthenia |
| <i>Renal and urinary disorders</i> | dysuria, micturition disorder, nocturia, polyuria, urinary retention, |
| <i>General disorders and administrative site conditions</i> | dysphonia, increased appetite, anorexia, increased weight, epistaxis, asthenia malaise, fatigue, rigors, excitability |

From post-marketing experience, isolated cases of acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction, have been reported with pseudoephedrine-containing products.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

See “**SIDE EFFECTS**”.

Overdosage Information: In the event of overdosage, general symptomatic and supportive treatment should be started immediately and maintained for as long as necessary.

Manifestations: They may vary from central nervous system depression (sedation, apnoea, diminished mental alertness, cyanosis, coma, cardiovascular collapse) to stimulation (insomnia, hallucination, tremors or convulsions) to death. Other signs and symptoms may be euphoria, excitement, tachycardia, palpitations,

PROFESSIONAL INFORMATION

thirst, perspiration, nausea, dizziness, tinnitus, ataxia, blurred vision and hypertension or hypotension.

Stimulation is particularly likely in children, as are

atropine-like signs and symptoms (dry mouth, fixed and dilated pupils, flushing, hyperthermia and gastrointestinal symptoms).

In large doses sympathomimetics may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscular weakness and tenseness, anxiety, restlessness and insomnia. Many patients can present a toxic psychosis with delusions and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsions, coma and respiratory failure.

The Oral LD₅₀ values for this combination product were greater than 525 and 1 839 mg/kg in mice and rats, respectively.

Treatment: Treatment is symptomatic and supportive.

IDENTIFICATION:

White to off-white, biconvex, coated tablets.

PRESENTATION:

Blister packs of 6 tablets.

STORAGE INSTRUCTIONS:

Store at or below 25 °C. Protect from moisture.

Keep out of reach of children.

REGISTRATION NUMBER:

27/5.8/0373

PROFESSIONAL INFORMATION

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:

Bayer (Pty) Ltd

27 Wrench Road

Isando

1600

South Africa

DATE OF PUBLICATION OF THIS PROFESSIONAL INFORMATION:

Date on the registration certificate: 14 January 1993

Date of the most recently revised professional information: 14 January 1993

Manufactured and packed by Schering-Plough Labo N.V., Belgium under licence by Bayer AG.